DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Clindamycin (Clindamycin Hydrochloride) - Indications and Dosage

 
 



INDICATIONS AND USAGE

Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (eg, erythromycin).

Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tuboovarian abscess, pelvic cellulitis and postsurgical vaginal cuff infection.

Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections.

Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections.

Pneumococci: Serious respiratory tract infections.

Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Clindamycin HCl and other antibacterial drugs, Clindamycin HCl should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

DOSAGE AND ADMINISTRATION

If significant diarrhea occurs during therapy, this antibiotic should be discontinued (see WARNING box).

Adults:   Serious infections —150 to 300 mg every 6 hours.

More severe infections —300 to 450 mg every 6 hours.

Pediatric Patients:   Serious infections —8 to 16 mg/kg/day (4 to 8 mg/lb/day) divided into three or four equal doses. More severe infections —16 to 20 mg/kg/day (8 to 10 mg/lb/day) divided into three or four equal doses.

To avoid the possibility of esophageal irritation, Clindamycin HCl Capsules should be taken with a full glass of water.

Serious infections due to anaerobic bacteria are usually treated with Clindamycin Phosphate Sterile Solution. However, in clinically appropriate circumstances, the physician may elect to initiate treatment or continue treatment with Clindamycin HCl Capsules.

In cases of β-hemolytic streptococcal infections, treatment should continue for at least 10 days.

HOW SUPPLIED

Clindamycin HCl Capsules USP (equivalent to 75 mg of Clindamycin) are Light Green and Light Green capsules imprinted logo "LANNETT" on the cap and "1381" on the body supplied in bottles of 100 (NDC 0527-1381-01) and 200 (NDC 0527-1381-04).

Clindamycin HCl Capsules USP (equivalent to 150 mg of Clindamycin) are Light Green and Light Blue Opaque capsules imprinted logo "LANNETT" on the cap and "1382" on the body supplied in bottles of 100 (NDC 0527-1382-01).

Clindamycin HCl Capsules USP (equivalent to 300 mg of Clindamycin) are Light Blue Opaque and Light Blue Opaque capsules imprinted logo "LANNETT" on the cap and "1383" on the body supplied in bottles of 16 (NDC 0527-1383-02) and 100 (NDC 0527-1383-01).

Dispense in a tight container with a child-resistant closure.

Store at 20° to 25° C (68° to 77° F) [see USP Controlled Room Temperature].

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014